Anaphylaxis drives Larimar’s setback, weak efficacy behind MoonLake’s: Clinical Report

The past few days brought share price losses for Larimar and MoonLake after clinical readouts, while PepGen and Enanta roughly doubled on clinical catalysts.

Larimar Therapeutics Inc. (NASDAQ:LRMR) reported Monday that daily subcutaneous injections of its recombinant FXN protein therapy nomlabofust increased skin FXN levels in patients with Friedreich ataxia, in the short and long term. However, the update was overshadowed by safety concerns...